


of UROLOGY®

Official Journal of the American Urological Association

Volume 207 | Number 6 | June 2022



Renal pelvis with low-grade upper tract urothelial carcinoma pre-therapy (A), and 6 weeks (B), 3 months (C) and 6 months (D) after completion of UGN-101 (mitomycin for pyelocalyceal solution; page 1302).

Secondary Polycythemia in Men Receiving Testosterone Therapy Increases Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism in First Year of Therapy

Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience

Association of Biochemically Verified Post-Diagnosis Smoking and Nonmuscle-Invasive Bladder Cancer Recurrence Risk

Visit **AUAjournals.org/jurology** for more information.

